ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Continuus Pharmaceuticals, a 2013 spin-off from the Novartis-MIT Center for Continuous Manufacturing, has netted $5 million in its second round of financing. The firm, one of C&EN’s 10 Start-Ups to Watch in 2016, develops continuous technology for drug manufacturing. It’s also developing off-patent drugs in collaboration with pharmacies and hospitals. It recently completed studies for a pilot plant integrating synthesis with formulation in one continuous process line and anticipates starting to build a commercial facility this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter